Diabetes and Cardiometabolic Risk Management
January 19, 2026 5:00 PM EST
The landscape of cardiometabolic disease management has changed drastically over the last 5 years. This CardioCore lecture will focus on guideline-directed management to optimize cardiometabolic risk among individuals with diabetes. There will be a particular focus on practical issues in management, especially for those individuals who are eligible for multiple risk reduction therapies (how to sequence therapies, council patients, etc).
Lecturer
Neha J. Pagidipati, MD MPH is an Associate Professor of Medicine and cardiometabolic disease prevention specialist at the Duke Clinical Research Institute.
She served as the Chief Research Fellow at the DCRI from 2016 to 2017 and has been involved in cardiometabolic disease prevention research since 2011. Before coming to Duke, she trained at Brigham and Women’s Hospital for internal medicine residency and then completed a two-year research fellowship in Global Women’s Health at the Brigham. During that time, she also obtained an MPH from the Harvard School of Public Health and studied cardiovascular disease prevention in women in India. Currently, she directs the Duke Cardiometabolic Prevention Clinic, and her research focuses on cardiometabolic disease prevention, with particular emphasis on lifestyle modification, weight management, lipid disorders, hypertension, and diabetes. Her research includes clinical trials, outcomes research, and implementation research, with the goal of improving evidence-based care for patients with high cardiovascular disease risk. She serves as the Associate Program Director of the Duke Clinical Research Institute Fellowship.
Moderator
Ann Marie Navar, MD, PhD, FASPC, is an Associate Professor of Medicine in the Division of Cardiology and a preventive cardiologist at the University of Texas Southwestern Medical Center. Dr. Navar’s research focuses on identifying and addressing gaps in the utilization of evidence-based therapies for cardiovascular disease prevention, with a particular focus on cholesterol-lowering therapies.
Her research includes using EHR and administrative data for observational research and cardiovascular outcomes trials. Dr. Navar is the Deputy Editor for Equity, Diversity, and Inclusion at JAMA-Cardiology and is the Secretary of the American Society of Preventive Cardiology.